1. Apologies for absence
Prof. Alasdair MacGowan, Prof. Krassimir Metodiev.

2. Minutes of meeting in Munich, 31 March 2007
The minutes were approved as a true record.

3. Matters arising
None.

4. EUCAST Steering Committee membership
Prof Kahlmeter reported that the current membership of the Steering Committee is:

Chairman: Prof Gunnar Kahlmeter, Sweden 2011
Scientific Secretary: Dr Derek Brown, UK 2011
Clinical Data Coordinator: Dr Rafael Canton, Spain 2011
BSAC: Prof Alasdair MacGowan, UK 2011
CRG: Dr Johan W. Mouton, Netherlands 2011
DIN: Dr Arne Rodloff, Germany 2011
NWGA: Dr Martin Steinbakk, Norway 2011
SFM: Prof Claude-James Soussy, France 2011
SRGA: Prof Ingrid Odenholt / Dr Christian Giske, Sweden 2011

The General Committee representatives will finish their terms on the Steering Committee after the meeting in April 2008 and the new representatives will be Dr Antti Nissinen (Finland) and Prof Paul Tulkens (ISC).

5. Confirmation of membership of EUCAST General Committee
5.1 The membership list was presented (the current list is attached). Representatives were asked to inform the Scientific Secretary if the current representative of their country has changed. They were also asked to ensure that they keep their national societies informed of EUCAST activities and to take part in the consultation process.

5.2 Anyone in the pharmaceutical and susceptibility device manufacturing industries may be part of the industry email network that is included in the consultation process (email gunnar.kahlmeter@ltkronoberg.se). Members changing email addresses were requested to inform Prof Kahlmeter and email correspondence
rejected twice will be removed from the list.

6. EUCAST progress report

Prof Kahlmeter summarised activities over the past year.

6.1 There have been five meetings of the Steering Committee. In addition there have been numerous presentations at a variety of meetings.

6.2 Harmonization of breakpoints for older agents will be completed in 2008. Groups to be completed are penicillins (almost finished) and oral cephalosporins. GK highlighted some outstanding issues with penicillins (different dosages, breakpoints for S. pneumoniae and N. meningitidis, Enterobacteriaceae and aminopenicillins). It has not yet been decided which oral cephalosporins will be included.

6.3 The different understanding and use of the intermediate category in different countries was highlighted. It was suggested that some educational activity may be needed, but it was noted that the intermediate category is defined in EUCAST documents and the ISO/CEN reference methods for antimicrobial susceptibility testing.

6.4 It was noted that the collaboration with EMEA in the setting of breakpoints for new agents according to the EMEA SOP (available on the EUCAST website) works very well - breakpoints have been set for daptomycin and tigecycline, and several more are in the pipeline.

6.5 Rationale documents explaining the basis of breakpoints are being prepared for each agent. Currently they are available for fluoroquinolones and new agents. Several more are close to completion and will be added to the EUCAST website as they are completed. It was suggested that they are needed as early as possible so that companies can understand the rationale if their suggestions were not accepted. Technical notes giving the background to EUCAST breakpoints are being published in CMI. New drugs will each have a technical note and existing drugs will have a technical note for each class of agents.

6.6 EUCAST has a very good relationship with ESCMID, which is very supportive and EUCAST greatly values the professional association with ESCMID.

6.7 The EUCAST website continues to be expanded and gives details of EUCAST activity including organisation, meetings, breakpoint tables, documents and guidelines. The data in the wild type distribution program on the website now includes over 13,000 organism-antibiotic distributions from different sources.

6.8 EUCAST continues to be financially supported by ESCMID, the National Breakpoint Committees of Steering Committee members and, on an interim basis, ECDC has continued the EU grant which finished in April 2007. ECDC has asked for proposals regarding susceptibility testing and, in conjunction with ESCMID, EUCAST has submitted a proposal.

7. EUCAST subcommittee reports

7.1 Prof Rodriguez-Tudela, chairman of the Antifungal Susceptibility Testing Subcommittee, reported that the subcommittee Steering Committee has met three times in the past year and the full committee meets at each ECCMID. Membership of the Subcommittee and Steering Committee are attached. They have developed fluconazole breakpoints and these, together with a rationale document and technical note, have been published. Breakpoints for other agents are now being considered and are at various stages of development. A definitive document on susceptibility testing of fementative yeasts has been published in CMI. A similar
document for filamentous fungi has just been completed and work is underway on a
document and on selection of control strains for non-fermentative yeasts (see
EUCAST website for documents). Workshops have been organised in Argentina
and Austria and another is planned for The Netherlands

7.2 Prof Kahlmeter reported that Dr Roland Leclercq has chaired the Expert Rules
Subcommittee over the past 18 months. Following extensive consultation, version
1.0 of the rules has been completed and is available from the EUCAST website.

7.3 Prof Rodloff reported on the anaerobe Subcommittee. Breakpoints for anaerobes
have been proposed and are being discussed and incorporated into breakpoint
tables by the Steering Committee. A reference methodology needs to be considered
as the ISO broth microdilution method is not appropriate for anaerobes. It was noted
that MIC distribution data on anaerobes can be submitted via Prof Rodloff or Prof
Kahlmeter (see EUCAST website for contact details).

8. EUCAST breakpoints
Prof Kahlmeter presented EUCAST breakpoint tables covering different groups of
antimicrobial breakpoints. All are now completed except penicillins (available very
soon) and oral cephalosporins (expected completion autumn 2008).

9. Future activities
Prof Kahlmeter reported that priorities for the next year were:
9.1 Secure future funding for EUCAST.
9.2 Completion of harmonization of breakpoints for penicillins and oral cephalosporins.
9.3 Apply the EMEA SOP to breakpoint setting for four to five new drugs.
9.4 Continue to develop the rationale documents on the EUCAST website and technical
notes in CMI.
9.5 Implementation of EUCAST breakpoints will be a major issue for the future. It is
expected that a disk diffusion breakpoints will be published for the Kirby-Bauer
technique, which is widely used. Breakpoints will be implemented in existing
methods and automated systems during 2009. The establishment of “National
Antibiotic Committees” in countries where these do not currently exist will be
encouraged in order to provide a route for national consultation in Europe on issues
of antimicrobial chemotherapy including susceptibility testing. Concern was
expressed about how different routine methods would relate to EUCAST
breakpoints, but it was explained that all methods should be related to the EUCAST
breakpoints tested by the ISO standard broth microdilution method and with
performance evaluated as defined in the ISO standard method (see EUCAST
website for details).

10. Any other business
10.1 Collaboration with breakpoint organisations outside Europe.
In response to a question from Prof Tulkens, Prof Kahlmeter replied that EUCAST
was very busy with European activities and had no immediate plans to discuss
collaboration with breakpoint organisations outside Europe. However, EUCAST has
good relationships with individuals in many countries and are happy to talk to any
organisation wanting to link with EUCAST.

11. The next meeting of the EUCAST Committee
General Meeting attendees signing the register, 19 April 2008

Jeff Alder                Bayer Healthcare
Naanashriti Alexander   Georgia
Jane Ambler              AstraZeneka
Arvydas Ambroziatis      Lithuania
Amanda Appleton          Oxoid
Gioia Babini             BD
Arta Balode              Latvia
Jacques Bille            Switzerland
Inge Boe                 Leo Pharma
Derek Brown              UK
Karen Bush               J&J
Rafael Canton            Spain
Manuel Cuenca-Estrella   Spain
Maj Dinesen              Leo Pharma
Peter Donnelly           Netherlands
Tracy Dooley             CLSI
Philippe Dufour          bioMérieux
Evelyn Ellis-Grosse      USA
Sheila Farnham           bioMérieux
Bob Flamm                J&J
Antti Hakanen            Finland
Pat Hogan                Pfizer
Yasir Ibrahim            USA
Judith Johnston          Siemens Healthcare Diagnostics
Ron Jones                JMI Laboratories
Manette Juvin            Bio-Rad
Katharina Kähler         bioMérieux
Gunnar Kahlmeter         Sweden
Ulrich Knauf             bioMérieux
Laura Koeth              Laboratory Specialists Inc
Ulrike Kunert            BD
Blairon Laurent          Belgium
Olga Lebdeva             Russia
Daniel Malait            Bio-Rad
Linda Miller             USA
Lupse Minaela            Romania
Helmut Mittermayer       Austria
Mary Motyl               Merck
Johan Mouton             Netherlands
James Poupard             Pharma Institute of Phila
Arne Rodloff             Germany
Juan-Luis Rodríguez-Tudela Spain
Arno Schmalreck          MBS
Carole Schubert          bioMérieux
Dee Shortridge           bioMérieux
Martin Springsklee       Bayer Healthcare
Martin Steinbakk         Norway
Olga Stetsiouk           Russia
Arjana Tambic-Andrasevic Croatia
Paul Tulkens             Belgium
Randy Turner             bioMérieux
Johan Van Eldere         Belgium
Jan Verhaegen            Belgium
Jost Winnemöller         Infectopharm
Barbara Zimmer           Siemens Healthcare Diagnostics

EUCAST General Meeting, Barcelona, 19 April 2008  4
**EUCAST General Committee April 2008**

**Chairman**
Dr Gunnar Kahlmeter

**Scientific Secretary**
Dr Derek Brown

**Clinical Data Coordinator**
Dr Rafael Canton

**National representatives**

<table>
<thead>
<tr>
<th>Country</th>
<th>Representative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>Prof. Helmut Mittermayer</td>
</tr>
<tr>
<td>Belgium</td>
<td>Prof. Jan Verhaegen</td>
</tr>
<tr>
<td>Bosnia</td>
<td>Dr Selma Uzunovic-Kamberovic</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Prof. Krassimir Metodiev</td>
</tr>
<tr>
<td>Croatia</td>
<td>Dr Arjana Tambic-Andrasevic</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>Dr Pavla Urbaskova</td>
</tr>
<tr>
<td>Denmark</td>
<td>Dr Niels Frimodt-Møller</td>
</tr>
<tr>
<td>Estonia</td>
<td>Dr Marina Ivanova</td>
</tr>
<tr>
<td>Finland</td>
<td>Dr Anti Hakkanen</td>
</tr>
<tr>
<td>France</td>
<td>Prof. Luc Dubreuil</td>
</tr>
<tr>
<td>Germany</td>
<td>Prof. Bernd Wiedemann</td>
</tr>
<tr>
<td>Greece</td>
<td>Prof. Alkiviadis Vatopoulos</td>
</tr>
<tr>
<td>Hungary</td>
<td>Dr Éva Bán</td>
</tr>
<tr>
<td>Iceland</td>
<td>Dr Karl Gustaf Kristinsson</td>
</tr>
<tr>
<td>Ireland</td>
<td>Dr Martin Cormican</td>
</tr>
<tr>
<td>Italy</td>
<td>Prof. Pietro Varaldo</td>
</tr>
<tr>
<td>Latvia</td>
<td>Dr A. Balode</td>
</tr>
<tr>
<td>Lithuania</td>
<td>Prof. Arvydza Ambrozaitis</td>
</tr>
<tr>
<td>Macedonia</td>
<td>No representative</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Prof. John Degener</td>
</tr>
<tr>
<td>Norway</td>
<td>Dr Martin Steinbakk</td>
</tr>
<tr>
<td>Poland</td>
<td>Prof. Waleria Hryniecz</td>
</tr>
<tr>
<td>Portugal</td>
<td>Prof. Jose Melo Cristino</td>
</tr>
<tr>
<td>Romania</td>
<td>No representative</td>
</tr>
<tr>
<td>Russia</td>
<td>Dr Olga Stetsiouk</td>
</tr>
<tr>
<td>Serbia</td>
<td>Dr Lazar Ranin</td>
</tr>
<tr>
<td>Slovak Republic</td>
<td>Prof. Milan Niks</td>
</tr>
<tr>
<td>Slovenia</td>
<td>Dr Jana Kolman</td>
</tr>
<tr>
<td>Spain</td>
<td>Dr Francisco Soriano</td>
</tr>
<tr>
<td>Sweden</td>
<td>Dr Barbro Olsson-Liljequist</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Prof. Jacques Bille</td>
</tr>
<tr>
<td>Turkey</td>
<td>Dr Deniz Gür</td>
</tr>
<tr>
<td>UK</td>
<td>Prof Alasdair MacGowan</td>
</tr>
<tr>
<td>Yugoslavia</td>
<td>No representative</td>
</tr>
</tbody>
</table>

**ISC**
Dr Paul Tulkens

**FESCI**
Dr David Livermore

**Pharmaceutical Industry**
Email network of any with an interest in antimicrobials

**Device Manufacturers**
Email network of any with an interest in antimicrobials
EUCAST Antifungal Susceptibility Testing Subcommittee

Steering Committee
Maiken Cavling Arendrup, Denmark
Cornelia Lass-Floerl, Austria
M. Cuenca-Estrella
Juan Luis Rodriguez-Tudela, Spain (Chairman)
Manuel Cuenca-Estrella, Spain
J Peter Donnelly, the Netherlands (Secretary)

Full Committee
Maiken Cavling Arendrup, Denmark
Malcolm Richardson, Finland
Eric Dannaoui, France;
Wolfgang Fegeler, Germany
Francesco Barchiesi, Italy
J Peter Donnelly, the Netherlands (Secretary)
Paul Verweij, the Netherlands
Peter Gaustad, Norway
Juan Luis Rodriguez-Tudela, Spain (Chairman)
Manuel Cuenca-Estrella, Spain
Erja Chryssanthou, Sweden
Jacques Bille, Switzerland
Caroline Moore, UK
David Denning, UK
Cornelia Lass-Floerl, Austria
Aristia Velegraki, Greece
Nikolay Klimko, Russia
Arno Schmalreck, Germany
Sevtap Arikan, Turkey